143 related articles for article (PubMed ID: 35536548)
1. Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease
Yan Y; Xing C; Xiao Y; Shen X; Zhang Z; He C; Shi JB; Liu M; Liu X
J Med Chem; 2022 May; 65(10):7334-7362. PubMed ID: 35536548
[TBL] [Abstract][Full Text] [Related]
2. A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-inflammatory activity evaluation in vivo.
Chen X; Yan Y; Cheng X; Zhang Z; He C; Wu D; Zhao D; Liu X
Bioorg Chem; 2023 Apr; 133():106402. PubMed ID: 36791618
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment.
Lin TE; Yang CR; Chou CH; Hsu JY; Chao MW; Sung TY; Hsieh JH; Huang WJ; Hsu KC
Biomed Pharmacother; 2022 Feb; 146():112459. PubMed ID: 34953394
[TBL] [Abstract][Full Text] [Related]
4. The discovery of a novel pyrrolo[2,3-b]pyridine as a selective CDK8 inhibitor offers a new approach against psoriasis.
Yan YY; Wang YM; Shen JH; Jian YJ; Lei CC; Wang Q; Liu C; Zhang XX; Liu XH
Biomed Pharmacother; 2024 Jun; 175():116705. PubMed ID: 38713949
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells.
Johannessen L; Sundberg TB; O'Connell DJ; Kolde R; Berstler J; Billings KJ; Khor B; Seashore-Ludlow B; Fassl A; Russell CN; Latorre IJ; Jiang B; Graham DB; Perez JR; Sicinski P; Phillips AJ; Schreiber SL; Gray NS; Shamji AF; Xavier RJ
Nat Chem Biol; 2017 Oct; 13(10):1102-1108. PubMed ID: 28805801
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors.
Hsu JY; Hsu KC; Sun C; Chou CH; Lin TE; Sung TY; Tseng HJ; Yen SC; Yang CR; Huang WJ
Biomed Pharmacother; 2023 Mar; 159():114258. PubMed ID: 36708700
[TBL] [Abstract][Full Text] [Related]
7. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia.
Zhang XX; Yan YY; Ma X; Xiao Y; Lei CC; Wang YM; Liu C; Wang Q; Zhang XT; Cheng WD; Liu XH
Eur J Med Chem; 2023 May; 251():115214. PubMed ID: 36889252
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy.
Yan YY; Zhang XX; Xiao Y; Shen XB; Jian YJ; Wang YM; She ZH; Liu MM; Liu XH
J Med Chem; 2022 Oct; 65(19):13216-13239. PubMed ID: 36126227
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Development of Cyclin-Dependent Kinase 8 Inhibitors.
Lv X; Tian Y; Li S; Cheng K; Huang X; Kong H; Liao C; Xie Z
Curr Med Chem; 2020; 27(32):5429-5443. PubMed ID: 30947649
[TBL] [Abstract][Full Text] [Related]
13. Binding patterns and structure-activity relationship of CDK8 inhibitors.
Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
[TBL] [Abstract][Full Text] [Related]
14. Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors.
Martínez-González S; García AB; Albarrán MI; Cebriá A; Amezquita-Alves A; García-Campos FJ; Martínez-Gago J; Martínez-Torrecuadrada J; Muñoz IG; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2020 Sep; 201():112443. PubMed ID: 32599324
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia.
Chen Z; Wang Q; Yan YY; Jin D; Wang Y; Zhang XX; Liu XH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305852. PubMed ID: 38258519
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and selective CDK8 inhibitors through FBDD approach.
Han X; Jiang M; Zhou C; Zhou Z; Xu Z; Wang L; Mayweg AV; Niu R; Jin TG; Yang S
Bioorg Med Chem Lett; 2017 Sep; 27(18):4488-4492. PubMed ID: 28802632
[TBL] [Abstract][Full Text] [Related]
17. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
Solum E; Hansen TV; Aesoy R; Herfindal L
Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
[TBL] [Abstract][Full Text] [Related]
18. Angel or Devil ? - CDK8 as the new drug target.
Wu D; Zhang Z; Chen X; Yan Y; Liu X
Eur J Med Chem; 2021 Mar; 213():113043. PubMed ID: 33257171
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer.
Li Y; Liu Y; Wu J; Liu X; Wang L; Wang J; Yu J; Qi H; Qin L; Ding X; Ren F; Zhavoronkov A
J Med Chem; 2023 Apr; 66(8):5439-5452. PubMed ID: 37029334
[TBL] [Abstract][Full Text] [Related]
20. TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression.
Urbano PCM; Aguirre-Gamboa R; Ashikov A; van Heeswijk B; Krippner-Heidenreich A; Tijssen H; Li Y; Azevedo VF; Smits LJT; Hoentjen F; Joosten I; Koenen HJPM
J Allergy Clin Immunol; 2018 Aug; 142(2):517-529. PubMed ID: 29248493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
